Mineralys Therapeutics Insider Buys 30,000 Shares on 30 June
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
mineralys-therapeuticsinsider-trading
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A Form 4 filing with the US Securities and Exchange Commission on 30 June disclosed that director G. Walcott Sarquis acquired 30,000 shares of Mineralys Therapeutics Inc. The transaction, executed at a weighted average price of $7.29 per share, represented a total investment of $218,700. This purchase increased the director's direct holdings in the clinical-stage biopharmaceutical company. The filing was publicly reported after market hours on the day of the trade.
Insider buying often signals confidence in a company's near-term prospects, particularly for pre-revenue biotech firms where value is tied to clinical milestones. The timing of this transaction is notable as Mineralys Therapeutics approaches a critical inflection point. The company's lead candidate, lorundrostat, is under investigation for the treatment of resistant hypertension with Phase 3 clinical trial data expected in the second half of 2026.
Historical precedents show significant stock movement following insider accumulation before pivotal data. In May 2024, Madrigal Pharmaceuticals saw shares appreciate over 200% in the six months leading to final NASH drug approval after a series of insider purchases. The current macroeconomic backdrop for biotech is characterized by elevated interest rates, which have pressured valuations for development-stage companies. This makes a substantial, non-scheduled insider buy a stronger contrarian signal.
The transaction appears to be driven by anticipation of the upcoming topline results from the Phase 3 trials, named ADVANCE-HTN. Positive data could position lorundrostat as a first-in-class aldosterone synthase inhibitor, addressing a multi-billion dollar market with limited treatment options. The purchase suggests insider belief that the trial is on track to meet its primary endpoints.
The purchase of 30,000 shares at $7.29 occurred when Mineralys Therapeutics had a market capitalization of approximately $310 million. The stock had declined 18% year-to-date prior to the transaction, underperforming the SPDR S&P Biotech ETF (XBI), which was down 5% over the same period. The biotech sector, as measured by the XBI, has faced headwinds with a average price-to-sales ratio dropping to 4.2 from a 2021 peak of 8.7.
This trade increased the director's disclosed holdings by 45%. The table below contrasts the trade details with recent company performance.
| Metric | Value |
|---|---|
| Shares Purchased | 30,000 |
| Price Per Share | $7.29 |
| Total Transaction Value | $218,700 |
| Mineralys Stock YTD Performance (Pre-Trade) | -18% |
Trading volume on the day of the purchase was 450,000 shares, meaning this single insider transaction accounted for 6.7% of the day's total volume. The company reported a cash and equivalents balance of $265 million as of its last quarterly filing, providing an estimated runway into 2027.
The direct purchase by a director may signal to the market that perceived risks surrounding the Phase 3 data are overstated. This could lead to increased institutional interest in MLYS shares ahead of the catalyst. A successful data readout would not only benefit Mineralys but could also lift the entire cardiorenal drug development sector. Peers like Cytokinetics (CYTK) and Ardelyx (ARDX) often see correlated movement on positive clinical news in adjacent therapeutic areas.
Conversely, companies marketing existing hypertension treatments, such as Merck with its blockbuster drug Merck's antihypertensives, could face long-term competitive pressure if lorundrostat demonstrates superior efficacy. The trade also implies a positive outlook on the regulatory pathway, suggesting insiders do not foresee significant FDA hurdles.
A counter-argument is that insider purchases are not infallible indicators and can sometimes reflect personal financial planning rather than corporate insight. The relatively modest size of the trade, while meaningful, does not constitute a massive bet that would fully de-risk the investment thesis. Market impact will ultimately depend on the binary outcome of the clinical trial.
Hedge fund positioning data indicates a short interest in MLYS of around 8% of float. A positive data catalyst could trigger a short squeeze, amplifying upward price movement. Flow has been neutral to slightly negative in recent weeks, but this insider activity may attract specialist healthcare funds looking for catalyst-driven opportunities.
The primary catalyst for Mineralys Therapeutics is the topline data readout from the Phase 3 ADVANCE-HTN trial, expected in Q4 2026. Investors should monitor clinicaltrials.gov for any updates to the estimated completion date. Secondary catalysts include potential presentations of Phase 2b data at major medical conferences like the American Heart Association Scientific Sessions in November 2026.
Key price levels for MLYS stock include a resistance zone between $8.50 and $9.00, which has contained rallies throughout 2025. A sustained break above $9.50 on heavy volume would indicate a bullish reversal of the prevailing downtrend. Support is established near the 52-week low of $6.20.
If the Phase 3 data is positive, watch for partnership announcements with larger pharmaceutical companies seeking to bolster their cardiovascular portfolios. A strategic collaboration would validate the commercial potential of lorundrostat and provide non-dilutive funding. Should the data disappoint, the stock would likely retreat to its cash-value floor, estimated near $5.00 per share based on the company's net cash position.
A Form 4 is a mandatory document filed with the SEC by corporate insiders—such as directors, officers, and beneficial owners—to report trades in their company's equity securities. Transactions must be reported within two business days. This filing provides transparency and allows investors to track the investment activities of those with the most intimate knowledge of the company's health and prospects, making it a closely watched data point for market participants.
The significance is contextual. For a company with a $310 million market cap, a purchase exceeding $200,000 by a director is a materially meaningful vote of confidence. It is more impactful than a smaller, routine purchase. The signal is strengthened because it was an open-market buy, requiring the insider to invest personal capital at prevailing prices, rather than being part of a pre-arranged trading plan which can sometimes dilute the signal's importance.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.